B7H3 CAR T-cell injection (TAA06 injection), which was developed by PersonGen Co., Ltd., was approved for testing in clinical trials by the Center for Drug Evaluation (CDE) of the State Drug Administration for relapsed/refractory neuroblastoma on July 4, 2022. Here, CD276 is linked to neuroblastoma.